hVIVO plc, a specialist contract research organisation (CRO), is experiencing rapid growth, establishing itself as the global leader in testing vaccines and therapeutics for infectious and respiratory diseases. By conducting human challenge clinical trials, the company offers early-stage clinical development services to a large and expanding client base. Notably, hVIVO counts four of the top ten largest biopharma companies globally among its repeat clients.
At the core of hVIVO’s business is a unique portfolio of 11 human challenge models, which continues to expand with new models currently in development. These models enable the company to test a wide range of products aimed at treating infectious and respiratory diseases. In addition to these capabilities, hVIVO excels in manufacturing challenge agents and offers specialist drug development and consultancy services through its Venn Life Sciences brand. Its lab services, provided under the hLAB brand, focus on virology, immunology, biomarker analysis, and molecular testing. The company also extends its expertise to include patient recruitment and trial site management for broader clinical field trial support.
hVIVO’s strategic move to Canary Wharf, a state-of-the-art facility, reflects its commitment to expanding and enhancing its operations, enabling it to continue providing world-class services to its global clients.
